OneCell Diagnostics is a cancer diagnostics startup based in India, with reports differing on whether its headquarters is Mumbai or Pune, that develops liquid biopsy tests for circulating tumor cells for oncologists and hospitals.

This Startup Deep Dive explains what OneCell Diagnostics does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

OneCell Diagnostics in Brief

• What it is: OneCell Diagnostics is an Indian Cancer liquid biopsy company based in Reports differ: Mumbai (India operations) or Foster City, California (US press release).
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company offers a blood-based liquid biopsy that detects cancer recurrence by capturing circulating tumor cells, branded OncoIndx Alfa in India and OncoIndx Ikon in the US.
• The test needs a 10 ml blood draw, which can be collected at home in two tubes, one for ctDNA and one for CTCs.
• It is delivered B2B2C through oncologists and hospitals, with partner hospitals including AIIMS, Apollo, Fortis and Tata Memorial.
• Funding: $16 million Series A (November 2024); no later round found.

OneCell Diagnostics Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is OneCell Diagnostics?

OneCell Diagnostics operates in the Cancer liquid biopsy space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to OneCell Diagnostics.

• The company offers a blood-based liquid biopsy that detects cancer recurrence by capturing circulating tumor cells, branded OncoIndx Alfa in India and OncoIndx Ikon in the US.
• The test needs a 10 ml blood draw, which can be collected at home in two tubes, one for ctDNA and one for CTCs.
• It is delivered B2B2C through oncologists and hospitals, with partner hospitals including AIIMS, Apollo, Fortis and Tata Memorial.
• In April 2025 it launched OncoIncytes, a multi-modal panel combining ctDNA, single-cell CTCs, RNA and proteomics, and rebranded as 1Cell.Ai.

The Origin Story of OneCell Diagnostics

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Mohan Uttarwar.
• Mohan Uttarwar is co-founder and CEO; a profile describes him as a Silicon Valley serial entrepreneur with 30+ years of experience and co-founder of Indx.ai since 2011.
• The company is described as a joint venture between India's Actorius Innovations and Research Pvt Ltd (a CTC test provider) and Silicon Valley-based Indx.ai.
• Founded in 2021, it later rebranded as 1Cell.Ai; a US parent, OneCell Diagnostics Inc, holds 79.8% of the Indian entity per Inc42 (March 2025).
• Inc42 lists Aravindan Vasudevan as a second founder; other sources do not, so reports differ.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Cancer liquid biopsy sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2021: company founded.
• November 2024: $16 million oversubscribed Series A led by Celesta Capital, with Tenacity Ventures, Cedars-Sinai, Eragon and Singularity Ventures; Nobel laureate James Rothman joined the board.
• By late 2024 (company-stated): nearly 10,000 patients tested, mainly in India, with about 120 staff in India and 24 in the US.
• April 2025: launched OncoIncytes and rebranded as 1Cell.Ai; the Foster City, California lab received CLIA certification.

OneCell Diagnostics Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Series A (November 2024): reported $16 Mn led by Celesta Capital, with Tenacity Ventures, Cedars Sinai, Eragon and Singularity Ventures.

How Does OneCell Diagnostics Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Diagnostic tests are delivered through oncologists and hospitals; patients pay for the test (B2B2C).
• Pricing is described by the CEO as about one-fifth of competitors' prices in the US.
• The test targets patients with recurrence risk, not first-time diagnosis, because of FDA regulatory considerations.
• It plans to launch in the US through local biomarker partners.

The Numbers: OneCell Diagnostics Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY24: revenue about Rs 21.5 crore (profile site, for 1Cell.Ai).
• FY25: revenue about Rs 41.9 crore, up 94.9% (same profile site; estimates from filings).
• Another aggregator quotes $19 million revenue for 2025 and no outside funding, which conflicts with the reported Series A, so it is disregarded.

Market Opportunity for OneCell Diagnostics

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• The company projects reaching over 1,000 oncologists and a million patients in the near term (company-stated).
• It positions around precision oncology for recurrence monitoring in India and the US.

Technology and Product at OneCell Diagnostics

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• A proprietary glass bead with antibodies captures circulating tumor cells.
• It combines CTC DNA, RNA and cell-surface protein testing, which the company calls True-Single-Cell-Multi-omics, with AI and machine learning analysis.
• The iCare / iDiscover applications help oncologists interpret reports.

Team and Culture at OneCell Diagnostics

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Mohan Uttarwar is CEO and co-founder.
• A clinical advisory board is chaired by Nobel laureate Dr. James Rothman.

OneCell Diagnostics Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for OneCell Diagnostics

• The company plans US expansion, which requires new market entry, regulatory approvals and reimbursement beyond its India base.
• Reports differ on its headquarters, founders and revenue.
• It competes with large US liquid biopsy firms.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

OneCell Diagnostics Growth Outlook: What to Watch

• Use Series A proceeds for US expansion of the test (reported).
• Scale operations in India and add the multi-modal OncoIncytes offering.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether OneCell Diagnostics can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where OneCell Diagnostics Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for OneCell Diagnostics

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for OneCell Diagnostics.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from OneCell Diagnostics

Studying a company in the Cancer liquid biopsy space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about OneCell Diagnostics.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate OneCell Diagnostics as a Startup

• Customer clarity: Can OneCell Diagnostics name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

OneCell Diagnostics is part of India’s growing Cancer liquid biopsy ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

OneCell Diagnostics FAQs: Frequently Asked Questions

What is OneCell Diagnostics?

OneCell Diagnostics is a cancer diagnostics startup based in India, with reports differing on whether its headquarters is Mumbai or Pune, that develops liquid biopsy tests for circulating tumor cells for oncologists and hospitals. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded OneCell Diagnostics?

OneCell Diagnostics was founded by Mohan Uttarwar, and the company reports a founding year of 2021.

How much funding has OneCell Diagnostics raised?

$16 million Series A (November 2024); no later round found. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does OneCell Diagnostics make money?

OneCell Diagnostics earns revenue from its Cancer liquid biopsy products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of OneCell Diagnostics?

Reported rivals include Guardant Health, Natera, Indian diagnostic companies. See the competitor comparison above for how they differ.

What are the main risks for OneCell Diagnostics?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Elevate Now — short profile of what is publicly known | Vitls — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.